Excerpts

However, in the multivariate analysis, although there was a clear trend toward significance, antiplatelet use did not reach statistical significance ( p = 0.068; Table 3 ). 3.3.

30.2%, p = 0.197); however, a statistical trend ( p = 0.068) in favour of adjuvant treatment exists when considering overall disease free survival (16 months (IQR: 10.5–27) vs. 14 months (IQR: 9–22)).

The day +30 Cum.Inc of bacterial bloodstream infections (BSI) tended to be higher in HLA-matched transplants (49.2%, p = 0.073), while HHV-6 reactivation showed a trend toward higher frequency in haploidentical transplants (22.4%, p = 0.068).

At the same time, PD-L1(+) showed a trend toward longer PFS (HR = 0.24; p = 0.068), but the analysis was limited by the small number of events and wide confidence intervals.

Clusters showed marginal significance ( p = 0.068) in the same direction, and all other comparisons were non-significant.

Low Ki-67 expression was significantly associated with longer OS ( p = 0.03) Similarly, the combination of low expression of p53 and PUMA in TC of primary tumors showed a marginally significant association with OS ( p = 0.068).

These ACT experiments showed an identical (almost significant: p = 0.0685) protective effect of the cells primed with either GL261-WT or -CIITA-expressing cells with respect to the transfer of cells from sham-operated mice.

3.12, n = 76, p = 0.0257) but not in the M or LAR subtypes, and showed a trend (H.R. 1.57, n = 171, p = 0.0687) towards poorer outcome in the BL-1 subtype ( Table 1 ) [ 43 ].

7.2 years; p = 0.001) and showed a trend for a correlation with shorter disease-free survival (median estimate 13.7 years vs. 9.7 years; p = 0.069) time after diagnosis ( Figure 2 ). 2.3.

In the present study, we found a statistically significant association between pretreatment NLR and OS using a cutoff value of ≥2 and a strong trend toward association with a cutoff value of ≥5 ( p = 0.069).

Likewise, patients harboring the KL status and concomitant no/low β-catenin membranous expression showed a trend correlating with decreased mOS vs. patients of KL status with retained, medium–high β-catenin membranous expression: 20.07 vs. 52.99; p = 0.069, Supplementary Table S20 . 3.6.7.

In the <45 year group (6 studies, 10 observations), the best-fitting model was linear, with an intercept of 65.45 ( p < 0.001) and a positive but borderline non-significant slope (β = 0.18, p = 0.069).

Multivariable analysis revealed that treatment modality had little impact on both LRC and OS; only GTV ≥ 100 cc showed borderline significance in LRC (HR 1.74, p = 0.069, Table 2 ). 3.4.

63%, p < 0.001, Figure 1 D); adjuvant therapies after lung metastasectomy had only a trend towards significance ( p = 0.069).

Positive PD-L1 staining determined at a threshold of 1% showed a trend towards improved survival in the entire cohort (70.3% vs. 57.4%, p = 0.07) in univariate analysis ( Figure 2 ).

CDX2 was near statistical significance for DFS (HR = 2.15, 95% CI (0.92–5.04), p = 0.070).

However, it is striking that nuclear/cytoplasmic expression of β-catenin has not been shown by itself in this meta-analysis to be significantly associated with poor survival, although a marked trend of effect is shown ( p = 0.07); this result is probably due to the paucity of primary studies addressing this question (3 studies, 255 patients).

Additionally, IGF1R mutations exhibited borderline significance (7.2% vs. 2.9%, p = 0.07).

The same trend was observed after 24 h (borderline significance, p = 0.07). 2.5.

There was, however, a trend towards significance between the PET and the CT data ( p -value = 0.070).

In addition, the MoRAL score showed the best calibration function with a non-significant p value ( p = 0.15) by the Hosmer-Lemeshow test; the WCM model and the AFP model, the second and third best models evaluated by c -index, were found to be less accurate with marginally significant p values ( p = 0.07, and p = 0.06, respectively).

Interestingly, females had statistically significant extended PFS compared to males, and although the impact on OS did not reach statistical significance, it was nearly significant ( p = 0.07).

Expression of miRNA-221 was not correlated with OS in the present patient cohort, however, in patients without neoadjuvant treatment miRNA-221 positive tumors showed a strong trend towards shortened OS ( p = 0.070) with a median OS of 64.0 months in miRNA-221 negative patients (95%CI not calculable) compared to a median OS of 22.1 month (95%CI 13.3–30.8 months).

The test for subgroup differences showed a trend toward statistical significance ( p = 0.07), thus no strong evidence of differential effects based on the method used to define sarcopenia was observed ( Supplementary File S6 ). - Overall survival (multivariate analyses, aHR): In the subgroup analysis for OS based on multivariate regression analyses’ reported outcomes, the pooled aHR for the 29 studies defining sarcopenia using SMI was 1.59 (1.40; 1.80), with substantial heterogeneity (I 2 = 79%, τ 2 = 0.06, p < 0.01).

First, we looked at CR/CRi status at FU90 and found a trend for an association of chromatin-modifier mutations with a higher CR/CRi rate ( p = 0.07), whereas mutations in tumor-suppressor genes showed a trend for a lower CR/CRi rate ( p = 0.07) ( Supplementary Table S4 ).